Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2000

View Archived Issues

Gemini Genomics and Genmab establish hMAb therapeutics alliance

Zycos begins phase II trial for treatment of cervical dysplasia

New Claritin formulation receives FDA marketing approval

Corixa/Coulter merger advances as Hart-Scott-Rodino waiting period expires

Angstrom receives SBIR grant for development of uPAR antagonist

Recent data support role for 5-HT2B receptor activation in development of cardiac valvulopathy

Fujisawa announces Japanese launch of Myslee

Vertex and Serono collaborate on caspase inhibitor development

SB commences clinical development of calcilytics for treatment of osteoporosis

Start of phase II trial of etomoxir to treat CHF announced

Actelion and Genentech collaborate on development and promotion of Tracleer

Vascular effects of first- and second-generation triptans compared in migraine patients

Novel in-licensed antifungal agent in late-stage preclinical development at Aressa

AHL-157, a new fibrate with promising hypolipidemic and hypoglycemic effects

Centrally acting muscle relaxants acting via 5-HT receptors discovered at Eisai

Kowa identifies aorta-selective ACAT inhibitor acting directly on atherosclerotic process

BioChem Pharma and Shire agree to merge

NHE inhibition has beneficial effects on LV remodeling in chronically stenosed rats

Dual Tx synthase and 5-LO inhibitors synthesized at Nikken

Japanese research team discovers new PTP inhibitors for diabetes

New agents for H. pylori-related disorders patented by Takeda

AHP and Ligand report preparation and use of new progesterone receptor modulators

Improvement in survival seen in cardiomyopathic hamsters treated with SCH00013

Roche presents new antitumor agents acting on cyclin-dependent kinases

Profile of new COX-2 inhibitor discussed at Japanese medicinal chemistry meeting

Two NDAs up for review at January Anti-Infective Drugs Advisory Committee meeting

Cancidas scheduled for FDA advisory committee review in mid-January

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...